PTC THERAPEUTICS, INC.PTCTEarnings & Financial Report
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Revenue
$213.2M
Gross Profit
N/A
Operating Profit
$-162.4M
Net Profit
$-65.9M
Gross Margin
N/A
Operating Margin
-76.2%
Net Margin
-30.9%
YoY Growth
-30.6%
EPS
$-0.85
PTC THERAPEUTICS, INC. Q4 FY2024 Financial Summary
PTC THERAPEUTICS, INC. reported revenue of $213.2M (down 30.6% YoY) for Q4 FY2024, with a net profit of $-65.9M (up 57.7% YoY) (-30.9% margin).
Key Financial Metrics
| Total Revenue | $213.2M |
|---|---|
| Net Profit | $-65.9M |
| Gross Margin | N/A |
| Operating Margin | -76.2% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
PTC THERAPEUTICS, INC. Q4 FY2024 revenue of $213.2M breaks down across 2 segments, led by Products at $154.7M (72.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $154.7M | 72.6% |
| Royalty | $58.2M | 27.3% |
PTC THERAPEUTICS, INC. Revenue by Segment — Quarterly Trend
PTC THERAPEUTICS, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Royalty) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Products | — | — | — | $153.4M |
| Royalty | — | $70.8M | — | $36.4M |
PTC THERAPEUTICS, INC. Annual Revenue by Year
PTC THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.7B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.7B |
| 2024 | $806.8M |
| 2023 | $937.8M |
| 2022 | $698.8M |
PTC THERAPEUTICS, INC. Quarterly Revenue & Net Profit History
PTC THERAPEUTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $164.7M | -22.7% | $-135.0M | -82.0% |
| Q3 FY2025 | $211.0M | +7.2% | $15.9M | 7.5% |
| Q2 FY2025 | $178.9M | -4.2% | $-64.8M | -36.3% |
| Q1 FY2025 | $1.2B | +459.7% | $866.6M | 73.7% |
| Q4 FY2024 | $213.2M | -30.6% | $-65.9M | -30.9% |
| Q3 FY2024 | $196.8M | +0.1% | $-106.7M | -54.2% |
| Q2 FY2024 | $186.7M | -12.7% | $-99.2M | -53.1% |
| Q1 FY2024 | $210.1M | -4.7% | $-91.6M | -43.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $210.1M | $186.7M | $196.8M | $213.2M | $1.18B | $178.9M | $211.0M | $164.7M |
| YoY Growth | -4.7% | -12.7% | 0.1% | -30.6% | 459.7% | -4.2% | 7.2% | -22.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.79B | $1.92B | $1.84B | $1.71B | $2.66B | $2.63B | $2.64B | $2.90B |
| Liabilities | $2.68B | $2.90B | $2.90B | $2.80B | $2.84B | $2.84B | $2.80B | $3.10B |
| Equity | $-893.9M | $-980.2M | $-1.05B | $-1.10B | $-185.8M | $-206.5M | $-155.8M | $-205.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $70.8M | $-71.5M | $-77.0M | $-30.0M | $870.1M | $-58.3M | $-66.3M | $-34.3M |